An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia

Trial Profile

An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Inotuzumab ozogamicin (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jun 2018 Results of this and other study presented at the 23rd Congress of the European Haematology Association.
    • 05 Jun 2018 Results from studies NCT01363297 and NCT01564784 presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Dec 2017 Results from NCT01363297 and NCT01564784 studies, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top